Key Takeaways:
Pfizer's GLP-1 weight management drug, Xianweiying, is now available for pre-order in China for 489 yuan, escalating the rivalry in the nation's rapidly growing weight-loss market.
The move pits Pfizer against established international and local players in a GLP-1 market that is booming globally. "By expanding access to the latest GLP-1 medications with upfront, clear pricing, we're making it easier for customers to get the treatments their health care providers prescribe," Tanvi Patel, vice president of Amazon Pharmacy, said recently about the drug class.
A listing on JD.com's e-commerce platform shows a 1.2 ml Xianweiying injector pen costs 489 yuan ($72), with shipping to begin on April 27. Pfizer's entry challenges market leaders like Novo Nordisk, whose Wegovy sales hit 260 million yuan ($38 million) in 2025 on platforms like Tmall and JD.com, and local firm Innovent Biologics, whose Xinermei drug recorded 416 million yuan ($61 million) in sales, according to a note from Jefferies.
The launch solidifies Pfizer's footing in a Chinese weight-loss drug market that analysts expect to be worth billions of dollars. Pfizer licensed the mainland China commercialization rights for Xianweiying, also known as ecnoglutide, from Hangzhou-based Sciwind in February. The drug is also approved in China as a treatment for Type 2 diabetes.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that have gained significant attention for their dual role in managing Type 2 diabetes and promoting weight loss. These drugs mimic a naturally occurring hormone that helps regulate metabolism. They increase insulin production, limit the release of sugar into the bloodstream, slow digestion, and signal to the brain a feeling of fullness. This combination of effects leads to reduced appetite and lower blood-sugar spikes, often resulting in significant weight loss over time.
Pfizer's entry into the Chinese market with Xianweiying is part of a broader corporate strategy to capture a share of the lucrative global obesity drug market. The company has also recently moved to acquire the obesity drug developer Metsera and another experimental GLP-1 drug, signaling a strong commitment to this therapeutic area. The competition is fierce, with companies like Amazon also entering the space by launching comprehensive GLP-1 management programs in the U.S. through its One Medical and Amazon Pharmacy divisions.
Pfizer's move into China's GLP-1 market signals a significant new revenue stream for the company. Investors will be closely watching the initial sales data and market share gains against competitors in the second half of 2026.
This article is for informational purposes only and does not constitute investment advice.
